Platform Assessment, Indication Prioritization & TPP Development to Inform Development Plan and Competitive Differentiation

The Client

• Biotechnology company with cell biology and genetic engineering platform developing a new generation of engineered cell therapies
• Core therapeutic areas include neurology, cardiology, and immunology

Challenge

• Develop defensible rationale and actionable plan to validate and leverage technology platform in AIID
• Assess and prioritize AIID indications (>150) based on relevance to technology platform and greatest therapeutic and commercial potential
• Develop target product profiles (TPPs) for top indications

Approach

• Assess technology platform and ID complementary autoimmune and inflammatory disease indications
• Evaluate, rank and prioritize indications based on scientific, clinical/regulatory and payer/market criteria
• Detailed assessments on prioritized indications and final indication rankings and development of TPPs

Valued Outcome

• Understanding of AIID landscape and competitive positioning of  client’s platform within landscape
• Selection of top AIID indications to best leverage technology platform and generate greatest near- and long-term value
• TPPs to inform development plan and differentiation